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Abstract: 
Background:  
Weight loss is common in patients with chronic heart failure (CHF) and is associated with 
adverse outcome. Activation of the sympathetic nervous system has been implicated in 
weight loss, wasting and cachexia. However, the effect of sympathetic antagonism on weight 
change in patients with CHF is not well defined.  
Methods: 
We evaluated changes in body weight, the incidence of cachexia (weight loss > 6%) and 
significant weight gain (>5%) in unselected patients with CHF due to left ventricular systolic 
dysfunction (LVSD) (LV ejection fraction (LVEF)<40%) and studied the effect of beta-
blockade on weight change.  
Results: 
Of the 1480 patients enrolled (median NTproBNP:1651ng/L, median LVEF:31%), 86% 
received beta-blocker, 11% never had beta-blocker and 3% discontinued beta-blocker 
between baseline and 1 year. 
Patients who did not have or tolerate beta-blocker were more likely to develop cachexia (23% 
vs 10%, p<0.001) and less likely to have significant weight gain (22% vs 24%, p<0.001) than 
patient who had beta-blocker.  
During a median follow up of 1876 days (IQR: 993-3052 days), 894 (60%) patients died. 
Higher body mass index (BMI) at baseline, weight gain and beta-blocker therapy were 
associated with better outcome. Patients who had all 3 features: beta-blocker therapy, 
baseline BMI ≥25 and significant weight gain had the best outcome (22% mortality at 5 
years).  
Conclusion: 
3 
 
Patients with CHF due to LVSD who receive beta-blocker were less likely to develop 
cachexia and more likely to have significant weight gain and better outcome compared to 
patients who did not receive or tolerate beta-blocker.   
 
(249 words) 
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Introduction: 
Many chronic conditions are associated with unintentional weight loss, which can be 
sufficient to be defined as cachexia when weight loss exceeds an arbitrary limit, often taken 
to be more than 5% in 12 months.
1
 The term ‘cachexia’ originates from the Greek words 
‘kakos’ and ‘hexis’, “bad condition”. Weight loss can occur from all body compartments; for 
patients with chronic heart failure (CHF), loss of muscle bulk is particularly important 
because it leads to reduced exercise capacity and worsened symptoms.
2
 The prevalence of 
cachexia in patients with CHF ranges between 5-15%
3
 and is strongly related to an adverse 
prognosis.
4
 Treatment trials in patients with cardiac cachexia have been discouraging so far.  
 
Activation of the sympathetic nervous system secondary to cardiac dysfunction is implicated 
in the development of muscle wasting and cachexia.
5
 Beta-adrenergic blockade reduces 
muscle catabolism and leads to weight gain in both in patients with cardiac and those with 
non-cardiac disorders.
6
 In the Carvedilol Prospective Randomised Cumulative Survival 
(COPERNICUS) trial, patients randomised to carvedilol were 33% less likely to become 
cachectic and 37% more likely to have a significant gain in weight.
7
 However, the patients in 
clinical trials are highly selected patients who may not be representative of the majority of 
patients with a condition. We wanted to explore the effects of beta-blockade on weight 
change in unselected patients with CHF to see if these findings are generally applicable.  
 
We explored the effects of sympathetic blockade on weight change and mortality in a large 
cohort of well-characterised patients with CHF. 
 
Methods 
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Consecutive patients referred between 2000 and February 2016 with suspected HF by either 
primary or secondary physicians to a community HF clinic, which serves a local population 
of about 500,000 people, were enrolled. Some patients had no prior diagnosis of HF and were 
treatment naive, therefore requiring initiation of guideline-recommended therapy; many 
others had a pre-existing diagnosis of HF and had already been initiated on treatment that 
might, however, require optimisation.    
 
Because a beta-blocker is recommended only for patients with HF and reduced left 
ventricular ejection fraction (LVEF), we included only those patients who had signs or 
symptoms of CHF and LVEF <40% (or at least moderate left ventricular systolic dysfunction 
by visual inspection if LVEF was not measured).
3
 (Appendix 1) 
 
Only patients who had weight recorded at baseline and at 1 year visit were included.  Patients 
with weight loss of >6% between baseline and 1 year were defined as having cachexia. A 
higher cut-off than the usual 5% was used to ensure we only included patients with 
significant weight change, as weight may fluctuate in patients with CHF as a result of 
changes in fluid status. Indeed, there is also evidence to suggest that a cut-off of 6% weight 
loss should be used to define the presence cachexia in patients with CHF.
7
  Patients with 
weight gain of ≥5% from baseline were classified as having significant weight gain.7 For 
patients who had 3 or more weight measurements recorded between baseline and 1 year visit 
(N=1361 (92%)), we also determined the variability of body weight by calculating the 
standard deviation of weight measurements recorded between baseline and 1 year.
8
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All patients had a full medical history and physical examination. Ischaemic heart disease 
(IHD) was defined as any previous medical history of acute coronary syndrome (ACS), 
percutaneous coronary intervention or coronary artery bypass surgery, or a diagnosis of 
myocardial ischemia based on invasive or non-invasive diagnostic tests. Cerebrovascular 
disease (CVD) was defined as any previous history of stroke or transient ischaemic attack 
(TIA). Peripheral vascular disease (PVD) was defined as a clinical history of the diagnosis.  
 
Blood was taken for standard haematology, biochemistry profile and N-terminal pro B-type 
natriuretic peptide (NTproBNP).  Patients were weighed in their casual wear without shoes. 
Body mass index (BMI) was calculated using the formula: BMI = weight in kilograms / 
(height in meters) squared.  
 
All patients were regularly seen in the HF clinic, usually at baseline, after 4 and 12 months, 
and then yearly, unless an expedited appointment was requested.  HF medications were 
optimised and diuretic dose adjusted to maintain euvolaemia and dry weight. Weight loss 
with dietary restriction was not routinely advised for overweight or obese patients, although a 
healthy diet and regular physical exercise was always recommended. 
 
We classified patients into 4 groups: 1) on beta-blocker therapy at baseline and 1 year; 2) not 
on beta-blocker therapy at baseline but on beta-blocker therapy at 1 year; 3) on beta-blocker 
therapy at baseline but not on beta-blocker therapy at 1 year; and 4) not on beta-blocker 
therapy at either time point.  As group 3 had very few patients (N=41 (3%)), we excluded this 
group from further analysis, although patients in group 3 seem to be sicker than patients in 
other beta-blocker treatment groups. 
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We also stratified patients into 3 BMI (kg/m
2
) categories: 1) underweight/normal 
(BMI<25.0), 2) overweight (BMI = 25.0-29.9) and 3) obese (BMI ≥ 30.0).9 
 
End points and follow-up 
Patients were followed up until 9
th
 March 2017. The primary endpoint was all-cause 
mortality. Our hospital is the only one in the region offering acute medical services. With 
previous consent from patients, we could access all their primary and secondary care records. 
Data regarding deaths were collected from the hospital’s electronic systems and were entered 
into a dedicated database, stored on a secure NHS server.  
 
Statistical analysis 
Continuous data are expressed as medians with interquartile ranges (IQR) (25
th
 to 
75
th
 centiles) and categorical data are expressed as N (%). Independent t tests and non-
parametric tests were used to compare medians across ordered groups for normally and non-
normally distributed variables, respectively.  The chi-squared test was used to compare 
proportions between groups.  Pearson’s correlation or Spearman’s correlation coefficients 
were used to assess the relationships between two variables. Log-transformation was applied 
when the data were very skewed.  
 
Cumulative incidence curves for all-cause mortality were constructed by the Kaplan-Meier 
method. The relationships between baseline BMI, beta-blocker treatment, degree of weight 
change and the risk of all-cause mortality were examined using Cox proportional hazards 
regression models.   
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All statistical analyses were performed using SPSS 22 (SPSS INc.,Chicago, IL, USA) and 
The Stata (14
th
 Version, StataCorp, TX, USA) statistical computer package. A two-tailed P 
value of <0.05 was considered significant in all analyses. 
 
The study conformed to the principles outlined in the Declaration of Helsinki and was 
approved by relevant ethical bodies. All subjects gave their written informed consent for their 
data to be used for research. 
 
Results  
Patient characteristics 
The baseline characteristics of the 1480 patients meeting the inclusion criteria are shown in 
table 1. 
 
Beta-blocker therapy  
Of the 3 beta-blocker therapy groups we focused on, patients who did not have beta-blocker 
therapy at any point were the oldest, most likely to be female, had the most severe symptoms 
and greatest signs of congestion. They were also the least likely to be on angiotensin 
converting enzyme inhibitor or angiotensin receptor blockers (ACEi/ARB). Patients who did 
not have beta-blocker therapy at baseline but had beta-blocker therapy at 1 year had the 
highest baseline NTproBNP. (Table 1a) 
 
Cachexia and significant weight gain  
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Cachexia occurred in 13% (N=185) and significant weight gain occurred in 24% (N=363) of 
patients. (Table 1b) 
 
Compared to those with significant weight gain or stable weight, those who developed 
cachexia were older, had higher BMI, worse symptoms and congestion, higher baseline 
NTproBNP, lower haemoglobin, worse renal function, were less likely to be on ACEi or 
mineralocorticoid receptor antagonist (MRA) and had a smaller fall in NTproBNP at 1 year. 
(Table 1b)  
 
Weight change and beta-blocker therapy 
The incidence of cachexia was higher in patients who did not have beta-blocker therapy than 
in patients who had beta-blocker therapy at baseline and 1 year (P<0.001). (Appendix 2a) The 
incidence of significant weight gain was higher in patients who had beta-blocker therapy 
either at baseline or initiated between baseline and 1 year than in patients who did not have 
beta-blocker therapy (P<0.001). (Appendix 2a)  
 
Weight change and baseline BMI 
The incidence of cachexia was higher in patients who were obese (BMI ≥ 30 kg/m2) than in 
patients who were overweight (BMI = 25.0-29.9 kg/m
2
) or normal/underweight (BMI <25 
kg/m
2
) (P <0.001). (Appendix 2b) The incidence of significant weight gain was lower in 
obese patients than in patients who were overweight or normal/ underweight (P <0.001). 
(Appendix 2b) 
 
Variability in weight in HF patients 
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Amongst the 1361 patients (92%) with three or more weight measurements during the first 
year of follow up, the median standard deviation in weight was 2.2 kg (IQR: 1.2-3.5). There 
was no difference in the variability of weight amongst patients between the different beta-
blocker therapy groups. (Table 1) Patients with BMI ≥ 30 had the greatest variability in body 
weight compared to patients in other BMI categories. (Appendix 3) 
 
Prognostic importance of weight change, baseline BMI and beta-blocker therapy 
Patients were followed from the end of the first year onward. During a median subsequent 
follow up of 1876 days (interquartile range: 993-3052 days), 894 (60%) patients died. 
Univariable and multivariable predictors of mortality are shown in Table 2. In univariable 
analysis, increasing BMI, significant weight gain and beta-blocker therapy were associated 
with a better outcome. In multivariable analysis, the development of cachexia and the 
absence of beta-blocker therapy were independently associated with increasing all-cause 
mortality.  
 
Kaplan-Meier curves for the relationship between weight change, beta-blocker therapy and 
outcome are shown in Figures 1a and 1b. Compared to patients with significant weight gain, 
those who developed cachexia had a 60% higher risk of all-cause death. (Figure 1a) 
Compared to patients who had beta-blocker therapy at baseline and 1 year, those who did not 
have beta-blocker therapy at both time points had a 90% higher risk of all-cause death. 
(Figure 1b) 
 
Tables 3a and 3b show the 1 year and 5 year mortality rates for patients divided by category 
of weight change, BMI and beta-blocker therapy. Patients with CHF who had the following 3 
11 
 
features: beta-blocker therapy both at baseline and 1 year, baseline BMI ≥25 and significant 
weight gain had the best outcome, while patients who did not have any of the above 3 
features (i.e.no beta-blocker therapy at either time point; baseline BMI<25 and cachexia) had 
the worst outcome (1 year mortality: 2% vs 18%, 5 year mortality: 22% vs 73%) (Tables 3a-
b). 
 
Discussion 
We found that amongst patients with CHF due to LVSD, those who were not receiving or 
were unable to take beta-blockers were more likely to develop cachexia and less likely to 
have significant weight gain than patients who received beta-blocker therapy. Significant 
weight gain and beta-blocker therapy were independently associated with improved survival. 
Our results are similar to those from the COPERNICUS trial, which studied 2289 patients 
with HF and left ventricular ejection fraction of <25%. Compared to patients randomised to 
placebo, those who received carvedilol were 33% less likely to become cachectic (weight loss 
of >6%) and 37% more likely to have a significant gain in weight (≥5%): these changes were 
associated with better outcome.
7
  
 
It is difficult to dissect the exact causal explanation for these findings. The beneficial effects 
of beta-adrenergic blockade on cardiac cachexia might be related to the role of the 
sympathetic activation on the development of cardiac cachexia.
10
 Patients with CHF have 
marked sympathetic activation; in particular cachectic patients have a higher level of 
circulating noradrenaline than non-cachectic patients with HF.
5 
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Sympathetic activation might contribute to cachexia by increasing total body energy 
expenditure
11
 and directly exerting a myotoxic effect on skeletal muscle.
12
  It also inhibits the 
secretion of leptin,
13
 stimulates release of pro-inflammatory cytokines
14
 and the development 
of insulin resistance,
15
 which can all lead to wasting of muscle and adipose cells. 
 
Beta-blockade reduces total body resting energy expenditure and prevents catecholamine-
induced myotoxicity.
 16
 Beta-blockade might also prevent weight loss by improving fatigue 
and exercise tolerance,
17
 perhaps in association with improved appetite. Inhibition of the 
renin-angiotensin system in patients with heart failure by angiotensin converting enzyme 
inhibitors and angiotensin receptor blockers also reduces the likelihood of weight loss,
18,19
  
suggesting that there is a strong relation between neurohormonal activation and weight loss. 
 
Although obesity is a risk factor for developing heart failure, once HF develops, a higher 
BMI is associated with better survival, a phenomenon sometimes called the obesity paradox. 
Current guidelines do not recommend weight loss in patients with CHF and BMI<35. 
20,21
 We 
have found that incident cachexia is more common in obese patients than normal weight 
patients. It is important to acknowledge that weight loss in obese patients carries a poor 
prognosis, even though weight loss might result in a body mass index still in the normal 
range.
22
 Patients who are a normal weight/BMI and who develop heart failure have less 
weight to lose than those who are obese. However, the prognosis seems to be related to 
proportional loss of weight, and so their prognosis is better than in obese patients who lose 
weight. Weight loss in an obese patient should therefore trigger the same if not more concern 
as weight loss in a patient with normal weight. 
13 
 
Weight loss is a poor prognostic sign and should alert the physician that the patient is 
deteriorating. Betablockers attenuate weight loss, emphasising the importance of their use in 
all patients with HeFREF as soon as possible after the diagnosis is made. 
 
Limitations: 
Our findings should be interpreted with caution for several reasons.  
Firstly, the definition of cachexia is arbitrary, and might not be appropriate in all patients 
with CHF. Changes in weight following treatment, including beta-blockers, ACEi and 
diuretics, might be related to changes in fluid status rather than loss of muscle or fat mass. 
However, it would be highly unlikely that many ambulatory patients with CHF have 
substantial (>5% of body weight) fluid accumulation; we also found that weight loss between 
baseline and 1 year was correlated with worsening rather than improved oedema status. 
 
Secondly, patients were enrolled between 2000 and 2016, and clinical practice has 
substantially changed over this period. We did not look at changes in the incidence of 
cachexia over time in our study. It is possible that the prevalence of cachexia is increasing as 
patients age and are at lower risk of sudden death compared to around 20 years ago.
23
 
 
Thirdly, we cannot ascertain whether weight loss was intentional or unintentional and we did 
not collect information on whether weight loss occurred in the presence of concomitant 
comorbities, such as cancer, which would have contributed to incident cachexia, and worse 
outcome, at least in some.  
 
14 
 
Fourthly, we only analysed weight change during baseline and 1 year follow-up, and thus 
those who died within a year, or did not attend 1-year follow-up visit, were not included in 
the analysis. Moreover, we have no data on weight changes from 1 year to time of event. 
 
Fifthly, the effect of beta-blockade on cachexia might be confounded by other factors, such as 
changes in other anti-HF medications or the use of cardiac resynchronisation therapy, both of 
which prevent weight loss in patients.
18 
 
In addition, we found that patients without beta-blockers at any time were the oldest and 
sickest; they also had the worst prognosis. It would be interesting to know whether survival in 
this group is related to the duration since heart failure diagnosis. We included patients from 
their first visit to the heart failure service and data from before presentation were not 
available. However, we have no reason to suspect that this particular group had heart failure 
for longer than other patients. 
 
Finally, this is a single observational study conducted in the UK; external validation of our 
results from other countries with different healthcare and social systems is needed. 
 
Conclusion:  
Around 13% of patients with CHF due to LVSD develop cachexia during one year follow up. 
Those who are not treated with beta-blockers are at higher risk of developing cachexia and 
have the worst survival. The findings support the role of sympathetic antagonism in the 
prevention of cachexia.  
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Tables: 
Table 1a. Baseline characteristics of patients with CHF according to beta-blocker treatment groups.  
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Table 1b: Baseline characteristics of patients with CHF according to categories of weight 
change.  
Table 2: Univariate and multivariate analysis for predictors of mortality. 
Table 3a: Percentage 1 year mortality according to categories of weight change, BMI and beta-
blocker therapy. 
Table 3b: Percentage 5 year mortality according to categories of weight change, BMI and beta-
blocker therapy. 
Figures: 
Figure 1a: Kaplan meier cumulative survival curve according to categories of weight change 
in patients with CHF.  
Figure 1b: Kaplan meier cumulative survival curve according to categories of beta-blocker 
therapy groups in patients with CHF. 
 
Appendices: 
Appendix 1: Recruitment of patients  
Appendix 2a: Degree of weight change in patients with CHF according to beta-blocker 
therapy groups.  The numbers within the bars represent the % of patients within each weight 
change category. P<0.001 
Appendix 2b: Degree of weight change in patients with CHF according to baseline BMI 
groups. The numbers within the bars represent the % of patients within each weight change 
category. P<0.001 
Appendix 3: Variability in weight in patients with CHF according to BMI categories. 
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Table 1a. Baseline characteristics of HeFREF patients according to beta-blocker treatment 
groups.  
 Beta-blocker treatment groups  Overall HF 
with LVSD 
(N=1480) 
Miss
ing  
P-
valu
e* 
betwe
en 
group
s 
BL&1y: 
BB 
(N=906)  
(61%) 
BL: no BB, 
1y:BB 
(N=367) 
(25%) 
BL&1y: No 
BB 
(N=166) 
(11%) 
BL: BB, 
1y:no BB 
(N=41) 
(3%) 
Demographics  
Age (years) 70 (61-77) 73 (66-79) 75 (69-81) 72 (66-80) 72 (63-78) 0 <0.0
01 
Sex (male), n (%) 704 (78) 265 (72) 112 (68) 33 (81) 1114 (75) 0 0.01 
BP systolic 
(mmHg) 
127 (113-
144) 
132 (117-
148) 
128 (115-
144) 
133 (108-
151) 
128 (114-
145) 
2 0.26 
BP diastolic 
(mmHg) 
77 (68-86) 78 (69-89) 77 (68-87) 73 (62-84) 77 (67-86) 3 0.01 
HR (bpm) 68 (60-80) 81 (71-95) 76 (66-89) 68 (56-83) 73 (63-86) 1 <0.0
01 
Heart rhythm, n 
(%) 
Sinus rhythm 
Atrial fibrillation 
 
709 (78) 
197 (22) 
 
276 (75) 
91 (25) 
 
126 (76) 
 40 (24) 
 
30 (73) 
11 (27) 
1141 (77) 0 0.59 
Paced rhythm, n 
(%) 
72 (8) 18 (5) 15 (9) 3 (7) 108 (7) 0 0.22 
LV impairment (%) 
Mild to moderate 
≥ moderate 
 
481 (53) 
420 (47) 
 
189 (51) 
178 (49) 
 
90 (54) 
76 (46) 
 
20 (49) 
21 (51) 
 
778 (53) 
702 (47) 
5 0.68 
Anthropometric measures  
Height (m) 1.71 (1.65-
1.77) 
1.69 (1.62-
1.75) 
1.67 (1.60-
1.73) 
1.70 (1.61-
1.76) 
1.70 (1.63-
1.76) 
0 <0.0
01 
Baseline weight 
(kg) 
81 (70-93) 78 (66-89) 76 (64-88) 76 (66-87) 79.3 (68.0-
91.0) 
0 <0.0
01 
Baseline BMI 
(kg/m
2
) 
27.8 (24.7-
31.1) 
27.4 (23.7-
30.6) 
27.1 (24.4-
30.5) 
26.0 (22.7-
30.6) 
27.5 (24.4-
30.9) 
0 0.06 
1 y weight (kg) 82 (70-94) 79 (67-90) 76 (65-87) 74 (66-88) 80 (68-92) 0 <0.0
01 
Weight change 
between baseline 
and 1 y visit (kg) 
+0.6 (-2.0 
to +3.7) 
+0.7 (-2.2 
to +4.8) 
0 (-3.9 to 
+3.0) 
0 (-2.5 to 
+3.2) 
+0.5 (-2.2 
to +3.9) 
0 0.14 
% weight change 
between baseline 
and 1 y visit  
+0.7 (-2.4 
to +4.4) 
+1.0 (-2.8 
to +6.1) 
0 (-4.8 to 
+4.2) 
0 (-3.2 to 
+4.2) 
+0.5 (-2.8 
to +4.9) 
0 0.17 
SD of weights 
between baseline 
and 1 y visit 
2.1 (1.2-
3.4) 
2.4 (1.3-
4.1) 
2.1 (1.3-3.9) 2.0 (1.1-3.5) 2.2 (1.2-
3.5) 
119 0.06 
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BMI categories 
(kg/m
2
) 
<25.0 
25.0-29.9 
≥30.0 
 
252 (28) 
366 (40) 
288 (32) 
 
125 (34) 
136 (37) 
106 (29) 
 
50 (30) 
69 (42) 
47 (28) 
 
16 (39) 
14 (34) 
11 (27) 
 
443 (30) 
585 (39) 
452 (31) 
0 0.32 
Weight change 
categories (%) 
Gain >5 
-6 to +5 
Loss of >6 
 
212 (24) 
601 (66) 
93 (10) 
 
107 (29) 
211 (58) 
49 (13) 
 
37 (22) 
91 (55) 
38 (23) 
 
7 (17) 
29 (71) 
5 (12) 
 
363 (25) 
932 (63) 
185 (12) 
0 <0.0
01 
Comorbidities  
IHD, n (%) 615 (68) 220 (60) 94 (57) 32 (78) 961 (65) 0 0.00
1 
Diabetes, n (%) 224 (25) 81 (22) 32 (19) 10 (24) 347 (23) 0 0.42 
Hypertension, n(%) 280 (31) 116 (32) 55 (33) 11 (27) 462 (31) 0 0.87 
CVA, n (%) 72 (8) 26 (7) 17 (10) 2 (5) 117 (8) 0 0.55 
PVD, n (%) 
 
64 (7) 36 (10) 9 (5) 4 (10) 113 (8) 0 0.23 
Clinical examination 
Baseline visit 
Lung crepitation, n 
(%) 
106 (12) 83 (23) 45 (27) 10 (24) 244 (17) 0 <0.0
01 
Raised JVP 
(1-4cm/ earlobe), n 
(%) 
99 (11) 91 (25) 37 (22) 9 (22) 236 (16) 0 <0.0
01 
Peripheral oedema, 
n (%) 
  None-trace 
  Ankle 
  ≥ Knee 
 
777 (86) 
96 (11) 
33 (3) 
 
256 (70) 
68(18) 
43 (12) 
 
115 (69) 
33 (20) 
18 (11) 
 
27 (66) 
9 (22) 
5 (12) 
 
1175 (79) 
206 (14) 
99 (7) 
0 <0.0
01 
NYHA III/IV , n 
(%) 
276 (30) 126 (34) 87 (52) 25 (61) 514 (35) 0 <0.0
01 
1 y visit 
Lung crepitation, n 
(%) 
41 (5) 29 (8) 12 (7) 2 (5) 84 (6) 0 0.09 
Raised JVP  
(1-4cm/ earlobe), n 
(%) 
41 (5) 19 (5) 12 (7) 2 (5) 74 (5) 0 0.53 
Peripheral oedema, 
n (%) 
  None-trace 
  Ankle 
  ≥ Knee 
 
835 (92) 
48 (5) 
23 (3) 
 
328 (89) 
26 (7) 
13 (4) 
 
149 (90) 
12 (7) 
5 (3) 
 
38 (93) 
2 (5) 
1 (2) 
 
1350 (91) 
88 (6) 
42 (3) 
0 0.78 
NYHA III/IV, n 
(%) 
187(21) 73 (20) 65 (39) 14 (34) 339 (23) 0 <0.0
01 
Bloods 
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Hb (g/dL) 13.6 (12.4-
14.7) 
13.6 (12.2-
14.7) 
13.6 (12.3-
14.5) 
13.0 (10.5-
14.4) 
13.6 (12.3-
14.7) 
0 0.10 
Urea (mmol/L) 7.1 (5.4-
9.6) 
6.9 (5.3-
9.2) 
7.1 (5.1-9.3) 8.0 (6.2-
15.4) 
7.1 (5.4-
9.5) 
0 0.08 
Creatinine 
(umol/L) 
104 (87-
129) 
107 (88-
128) 
105 (90-134) 120 (99-180) 105 (88-
131) 
0 0.00
5 
K+ (mmol/L) 4.4 (4.2-
4.7) 
4.3 (4.0-
4.6) 
4.3 (4.0-4.7) 4.5 (4.1-4.8) 4.4 (4.1-
4.7) 
2 0.00
9 
Na+ (mmol/L) 139 (137-
140) 
139 (137-
141) 
139 (136-
141) 
139 (137-
141) 
139 (137-
141) 
0 0.52 
Baseline 
NTproBNP (ng/L) 
1446 (644-
3096) 
1880 (826-
4288) 
1642 (663-
3769) 
2498 (829-
6312) 
1593 (694-
3451) 
37 0.00
1 
1y NTproBNP 1004 (388-
2194) 
1235 (484-
2995) 
1083 (461-
2221) 
1757 (717-
3747) 
1081 (425-
2357) 
59 0.00
7 
Change in 
NTproBNP 
between baseline 
and 1 y 
-102 (-910 
to +52) 
-146 (-1361 
to +146) 
-25 (-947 to 
+110) 
-652 (-2862 
to +219) 
-100 (-1040 
to +70) 
79 0.44 
% change 
NTproBNP 
between baseline 
and 1 y 
-15 (-53 to 
+8) 
-13 (-60 to 
+22) 
-6 (-53 to 
+16) 
-37 (-64 to 
+25) 
-13 (-55 
to+12) 
79 0.89 
Treatment 
Baseline treatment 
ACEi, n (%) 723 (80) 245 (67) 102 (61) 29 (71) 1099 (74) 0 <0.0
01 
ARB, n (%) 89 (10) 31 (8) 15 (9) 6 (15) 141 (10) 0 0.60 
ACEi/ ARB, n (%) 809 (89) 274 (75) 115 (69) 34 (83) 1232 (83) 0 <0.0
01 
MRA 356 (39) 69 (19) 33 (20) 16 (39) 474 (32) 0 <0.0
01 
Loop diuretics, n 
(%) 
698 (77) 275 (75) 131 (79) 34 (83) 1138 (77) 0 0.57 
Thiazide diuretics, 
n(%) 
24 (3) 11 (3) 13 (8) 1 (2) 49 (3) 0 0.00
7 
Statin, n (%) 559 (62) 145 (40) 61 (37) 28 (68) 793 (54) 0 <0.0
01 
Digoxin, n (%) 142 (16) 73 (20) 29 (18) 8 (20) 252 (17) 0 0.32 
 
1 y treatment 
ACEi, n (%) 719 (79) 298 (81) 119 (72) 23 (56) 1159 (78) 0 <0.0
01 
ARB, n (%) 134 (15) 49 (13) 31 (19) 5 (12) 219 (15) 0 0.42 
ACEi/ ARB, n (%) 845 (93) 342 (93) 146 (88) 28 (68) 1361 (92) 0 <0.0
01 
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MRA 428 (47) 120 (33) 64 (39) 17 (42) 629 (43) 0 <0.0
01 
Loop diuretics, n 
(%) 
701 (77) 302 (82) 139 (84) 34 (83) 1176 (80) 0 0.10 
Thiazide diuretics, 
n (%) 
28 (3) 8 (2) 11 (7) 4 (10) 51 (3) 0 0.00
7 
Statin, n (%) 611 (67) 188 (51) 70 (42) 22 (54) 891 (60) 0 <0.0
01 
Digoxin, n (%) 175 (19) 79 (22) 55 (33) 11 (27) 320 (22) 0 0.00
1 
 
HF= heart failure, LVEF= left ventricular ejection fraction, NTProBNP= N-terminal Pro Brain Natriuretic Peptide, HeFREF= heart failure 
with reduced ejection fraction, HeFNEF= heart failure with normal ejection fraction, BP= blood pressure, HR = heart rate, 1y= 1 year, 
BMI= body mass index, SD= standard deviation, IHD= ischaemic heart disease, CVA= cerebral vascular accident, PVD= peripheral 
vascular disease, JVP= jugular venous pressure, NYHA= New York Heart Association class, Hb= haemoglobin, K+= potassium, Na= 
sodium, ACEi= angiotensin converting enzyme inhibitor, ARB= angiotensin receptor blocker, MRA= mineralocorticoid receptor antagonist,  
BL= baseline, BB= Beta-blocker  
*P-value for trend except when there are > 2 categories (e.g. NYHA class ) 
 
Table 1b: Baseline characteristics of HF patients according to categories of weight 
change and BMI. 
 Weight change categories Missi
ng 
P-
value
* 
betwe
en 3 
group
s 
Weight↓ 
>6% 
(N=185)  
(13%) 
Weight change: -
6% to +5% 
(N=932) 
(63%) 
Weight↑ 
>5% 
(N=363) 
(N=24%) 
Demographics 
Age (years) 73 (66-78) 72 (64-78) 70 (62-77) 0 0.007 
Sex (male), n (%) 125 (68) 730 (78) 259 (71) 0 0.001 
BP systolic 
(mmHg) 
126 (110-
142) 
130 (116-147) 125 (111-
141) 
2 0.003 
BP diastolic 
(mmHg) 
75 (67-84) 77 (68-86) 77 (65-87) 3 0.32 
HR (bpm) 77 (66-92) 71 (61-84) 76 (66-89) 1 <0.00
1 
Heart rhythm, n 
(%)  
Sinus rhythm 
Atrial fibrillation 
 
133 (72) 
52 (28) 
 
731 (78) 
201 (22) 
 
277 (76) 
86 (24) 
0 0.14 
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Paced rhythm, n 
(%) 
16 (9) 73 (8) 19 (5) 0 0.20 
LV impairment, 
n (%) 
Mild to moderate 
≥ moderate 
 
98 (53) 
87 (47) 
 
516 (56) 
411 (44) 
 
166 (46) 
197 (54) 
5 0.002 
Anthropometric measures 
Height (m) 1.68 (1.61-
1.76) 
1.70 (1.64-1.76) 1.69 (1.62-
1.75) 
0 0.01 
Baseline BMI 
(kg/m
2
) 
28.6 (24.8-
32.7) 
27.9 (24.9-31.1) 25.9 (22.9-
29.2) 
0 <0.00
1 
BMI categories 
(kg/m
2
) 
<25.0 
25.0-29.9 
≥30.0 
 
51 (28) 
57 (31) 
77 (41) 
 
236 (25) 
396 (43) 
300 (32) 
 
156 (43) 
132 (36) 
75 (21) 
0 <0.00
1 
Baseline weight 
(kg) 
80 (68-95) 81 (70-91) 75 (62-87) 0 <0.00
1 
1 y weight (kg) 71 (61-84) 81 (70-92) 83 (69-96) 0 <0.00
1 
SD of weights 
between baseline 
and 1 y visit 
4.2 (3.3-6.3) 1.5 (0.9-2.1) 3.8 (2.8-
5.3) 
119 <0.00
1 
Comorbidities 
IHD, n (%) 115 (62) 631 (68) 215 (59) 0 0.01 
Diabetes, n (%) 55 (30) 201 (22) 91 (25) 0 0.04 
Hypertension, 
n(%) 
57 (31) 296 (32) 109 (30) 0 0.83 
CVA, n (%) 15 (8) 74 (8) 28 (8) 0 0.99 
PVD, n (%) 15 (8) 71 (8) 27 (7) 0 0.96 
Clinical examination 
Baseline visit 
Lung crepitation, 
n (%) 
47 (25) 140 (15) 57 (16) 0 0.002 
Raised JVP  
(1-4cm/ earlobe), 
n (%) 
44 (24) 133 (14) 59 (16) 0 0.005 
Peripheral 
oedema, n (%) 
  None-trace 
  Ankle 
  ≥ Knee 
 
121 (66) 
32 (17) 
32 (17) 
 
755 (81) 
125 (13) 
52 (6) 
 
299 (82) 
49 (14) 
26 (4) 
0 <0.00
1 
NYHA III/IV, n 
(%) 
85 (46) 312 (33) 117 (32) 0 0.02 
1 y visit 
Lung crepitation, 
n (%) 
10 (5) 57 (6) 17 (5) 0 0.60 
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Raised JVP 
(1-4cm/ earlobe), 
n (%) 
13 (7) 41 (4) 20 (6) 0 0.29 
Peripheral 
oedema, n (%) 
  None-trace 
  Ankle 
  ≥ Knee 
 
165 (89) 
23 (7) 
8 (4) 
 
853 (91) 
56 (6) 
23 (3) 
 
332 (91) 
20 (6) 
11 (3) 
0 0.69 
NYHA III/IV, n 
(%) 
59 (32) 215 (23) 65 (18) 0 0.002 
Bloods  
Hb (g/dL) 13.2 (12.0-
14.4) 
13.6 (12.4-14.7) 13.7 (12.3-
14.8) 
0 0.18 
Urea (mmol/L) 7.9 (5.6-
10.7) 
6.8 (5.3-9.0) 7.5 (5.4-
10.0) 
0 <0.00
1 
Creatinine 
(umol/L) 
114 (90-138) 104 (88-128) 104 (85-
134) 
0 0.10 
K+ (mmol/L) 4.3 (4.1-4.7) 4.4 (4.1-4.7) 4.3 (4.0-
4.7) 
2 0.50 
Na+ (mmol/L) 139 (137-
141) 
139 (137-141) 138 (136-
140) 
0 0.06 
Baseline 
NTproBNP 
(ng/L) 
2090 (929-
5531) 
1463 (645-3131) 1784 (724-
3769) 
37 <0.00
1 
1y NTproBNP 1801 (660-
4431) 
1040 (421-2206) 896 (346-
2254) 
59 <0.00
1 
Change in 
NTproBNP 
between baseline 
and 1 y 
0 (-1011 to 
+219) 
-63 (-913 to 
+106) 
-380 (-1543 
to 0) 
79 <0.00
1 
% change 
NTproBNP 
between baseline 
and 1 y 
0 (-48 to 
+17) 
-10 (-48 to +16) -33 (-70 to 
0) 
79 <0.00
1 
Treatment 
Baseline treatment 
ACEi, n (%) 120 (65) 697 (75) 282 (78) 0 0.004 
ARB, n (%) 24 (13) 88 (9) 29 (8) 0 0.17 
ACEi/ ARB, n 
(%) 
144 (78) 779 (84) 309 (85) 0 0.09 
MRA, n (%) 53 (29) 285 (31) 136 (38) 0 0.03 
Loop diuretics, n 
(%) 
152 (82) 682 (73) 304 (84) 0 <0.00
1 
Thiazide 
diuretics, n (%) 
8 (4) 29 (3) 12 (3) 0 0.70 
Statin, n (%) 85 (46) 541 (58) 167 (46) 0 <0.00
1 
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Digoxin, n (%) 37 (20) 130 (14) 85 (23) 0 <0.00
1 
1y treatment 
ACEi, n (%) 134 (72) 733 (79) 292 (80) 0 0.09 
ARB, n (%) 20 (11) 142 (15) 57 (16) 0 0.26 
ACEi/ ARB, n 
(%) 
154 (83) 862 (93) 345 (95) 0 <0.00
1 
MRA, n (%) 81 (44) 398 (43) 150 (41) 0 0.84 
Loop diuretics, n 
(%) 
160 (87) 719 (77) 297 (82) 0 0.007 
Thiazide 
diuretics, n (%) 
13 (7) 27 (3) 11 (3) 0 0.02 
Statin, n (%) 96 (52) 597 (64) 198 (55) 0 <0.00
1 
Digoxin, n (%) 65 (35) 175 (19) 80 (22) 0 <0.00
1 
Beta-blocker 
groups, n(%) 
BL&1y: BB 
BL: no BB, 1y: 
BB 
BL: BB, 1y: no 
BB 
BL&1y: no BB 
 
93 (50) 
49 (26) 
5 (3) 
38 (21) 
 
601 (64) 
211 (23) 
29 (3) 
91 (10) 
 
212 (58) 
107 (30) 
7 (2) 
37 (10) 
0 <0.00
1 
 
HF= heart failure, LVEF= left ventricular ejection fraction, NTProBNP= N-terminal Pro Brain Natriuretic 
Peptide, HeFREF= heart failure with reduced ejection fraction, HeFNEF= heart failure with normal 
ejection fraction, BP= blood pressure, HR = heart rate, 1y= 1 year, BMI= body mass index, SD= standard 
deviation, IHD= ischaemic heart disease, CVA= cerebral vascular accident, PVD= peripheral vascular 
disease, JVP= jugular venous pressure, NYHA= New York Heart Association class, Hb= haemoglobin, 
K+= potassium, Na= sodium, ACEi= angiotensin converting enzyme inhibitor, BL= baseline, BB= Beta-
blocker  
*P-value for trend except when there are > 2 categories (e.g. NYHA class) 
 
Table 2: Univariate and multivariate analysis for predictors of mortality in patients with HeFREF. 
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Worse outcome per 
unitary increase 
Univariate analysis Multivariate analysis 
HR 
(95% CI) 
Wald 
X
2
 
P HR 
(95% CI) 
Wald 
X
2
 
P 
Age (years) 1.06 
(1.05-1.07) 
226.1 <0.001 1.04 
(1.03-1.05) 
71.7 <0.001 
Diastolic BP (mmHg) 0.99 
(0.98-0.99) 
36.6 <0.001 0.99 
(0.99-1.00) 
8.1 0.004 
AF  
(yes vs no) 
1.33 
(1.15-1.55) 
13.9 <0.001    
Paced rhythm  
(yes vs no) 
1.30 
(1.02-1.68) 
4.3 0.04    
LV impairment 
 Mild/ moderate  
 > moderate 
 
Referent 
1.15 
(1.01-1.31) 
 
 
4.2 
 
 
0.04 
   
Baseline BMI (kg/m
2
) 0.97 
(0.96-0.99) 
18.3 <0.001    
Weight change in 1 year 
(kg) 
0.98 
(0.97-0.99) 
9.1 0.002    
% weight change in 1 year 0.99 
(0.98-1.00) 
8.8 0.003    
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Weight change categories 
weight gain >5%  
weight change -6 to +5% 
   
weight loss >6% 
 
Referent 
1.06 
(0.90-1.24) 
1.62 
(1.30-2.02) 
 
 
0.5 
 
18.7 
 
 
0.49 
 
<0.001 
 
Referent 
1.15 
(0.96-1.38) 
1.42 
(1.10-1.84) 
 
 
2.2 
 
7.2 
 
 
0.14 
 
0.007 
NYHA class 
(III/IV vs I/II) 
1.59 
(1.39-1.81) 
44.7 <0.001    
Oedema  
(> ankle vs none/ ≤ankle) 
1.55 
(1.21-1.98) 
12.2 <0.001    
Diabetes  
(Yes vs no) 
1.22 
(1.05-1.43) 
6.6 0.01 1.23 
(1.03-1.48) 
5.3 0.02 
IHD 
(Yes vs no) 
1.27 
(1.10-1.46) 
10.5 0.001 1.36 
(1.14-1.62) 
12.1 <0.001 
HTN 
(Yes vs no) 
1.23 
(1.07-1.41) 
8.6 0.003 1.27 
(1.08-1.49) 
8.3 0.004 
CVA/ TIA 
(Yes vs no) 
1.37 
(1.10-1.71) 
8.1 0.004    
PVD 
(Yes vs no) 
1.65 
(1.33-2.06) 
20.5 <0.001 1.59 
(1.24-2.04) 
13.1 <0.001 
Hb (g/dL) 0.86 
(0.83-0.89) 
54.8 <0.001    
Urea (mmol/L) 1.08 
(1.07-1.09) 
155.6 <0.001 1.04 
(1.02-1.05) 
19.4 <0.001 
Creatinine (µmol/L) 1.01 
(1.00-1.01) 
122.7 <0.001    
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Na+ (mmol/L) 0.97 
 (0.95-0.99) 
6.6 0.01    
logNTproBNP 2.54 
(2.21-2.91) 
178.6 <0.001 1.89 
(1.58-2.25) 
48.4 <0.001 
ACEi/ARB treatment 
BL & 1y: ACEi/ ARB  
BL: no ACEi/ARB; 
1 yr: ACEi/ARB 
BL: ACEi/ ARB; 
1y: no ACEi/ARB  
BL & 1y: no ACEi/ARB 
 
 
Referent 
1.13 
(0.94-1.36) 
1.62 
(1.23-2.14) 
1.33 
(0.93-1.91) 
 
 
1.6 
 
11.6 
 
2.4 
 
 
0.21 
 
0.001 
 
0.12 
   
BB treatment 
BL & 1y: BB  
BL: no BB, 1y: BB  
 
BL & 1y: no BB 
 
Referent 
1.38 
(1.18-1.60) 
1.87 
(1.54-2.28) 
 
 
17.1 
 
40.3 
 
 
<0.001 
 
<0.001 
 
Referent 
1.15 
(0.97-1.37) 
1.47  
(1.17-1.85) 
 
 
2.4 
 
10.7 
 
 
0.12 
 
0.001 
Digoxin 
(Yes vs no) 
1.23 
(1.04 -1.47) 
5.7 0.02    
 
 
BP=blood pressure, AF= atrial fibrillation, LVEF= left ventricular ejection fraction, BMI= body mass index, NYHA= New York heart 
association, IHD= ischaemic heart disease, HTN= hypertension, CVA/TIA= cerebrovascular accident/ transient ischaemic attack, PVD= 
peripheral vascular disease, Hb= haemoglobin, Na=sodium, NTproBNP= N-terminal pro B-type natriuretic peptide, ACEi= angiotensin 
converting enzyme inhibitor, ARB= angiotensin receptor blocker, BB= beta-blocker, HR= hazard ratio, CI= confidence Interval, Wald X2 = 
wald chi square. 
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 Weight change & BMI categories 
BMI ≥ 25 BMI < 25 
Weight↑ 
>5%  
Weight 
change  
-6% to +5% 
Weight↓ 
>6%  
 
Weight↑ 
>5%  
Weight 
change  
-6% to +5% 
Weight↓ 
>6%  
 
B
et
a
-b
lo
ck
er
 t
re
a
tm
en
t 
g
ro
u
p
s 
BL&1y 
BB 
2% 
(N=132) 
3% 
(N=455) 
8% 
(N=67) 
5% 
(N=80) 
6% 
(N=146) 
15% 
(N=26) 
BL: no BB 
1y: BB 
4% 
(N=55) 
6% 
(N=151) 
8% 
(N=36) 
6% 
(N=52) 
8% 
(N=60) 
15% 
(N=13) 
BL&1y  
no BB 
5% 
(N=19) 
13% 
(N=70) 
11% 
(N=27) 
17% 
(N=18) 
14% 
(N=21) 
18% 
(N=11) 
Table 3a: Percentage 1 year mortality in patients with HeFREF according to categories of 
weight change, BMI and beta-blocker therapy. 
 
 
 Weight change & BMI categories 
BMI ≥ 25 BMI < 25 
Weight↑ 
>5%  
Weight 
change  
-6% to +5% 
Weight↓ 
>6%  
 
Weight↑ 
>5%  
Weight 
change  
-6% to +5% 
Weight↓ 
>6%  
 
B
et
a
-b
lo
ck
er
 t
re
a
tm
en
t 
g
ro
u
p
s 
BL&1y 
BB 
22% 
(N=132) 
28% 
(N=455) 
42% 
(N=67) 
31% 
(N=80) 
39% 
(N=146) 
46% 
(N=26) 
BL: no BB 
1y: BB 
40% 
(N=55) 
34% 
(N=151) 
42% 
(N=36) 
42% 
(N=52) 
42% 
(N=60) 
46% 
(N=13) 
BL&1y  
no BB 
37% 
(N=19) 
50% 
(N=70) 
56% 
(N=27) 
56% 
(N=18) 
38% 
(N=21) 
73% 
(N=11) 
Table 3b: Percentage 5 year mortality in patient with HeFREF according to categories of weight 
change, BMI and beta-blocker therapy. 
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Highlights 
 Around 13% of patients with CHF due to LVSD develop cachexia during one year 
follow up.  
 Those who are not treated with beta-blockers are at higher risk of developing cachexia 
and have the worst survival.  
 The findings support the role of sympathetic antagonism in the prevention of 
cachexia.  
 
Figure 1
Figure 2
